Bethanechol

Limits on what this shows

• Null and contrary findings: No human data. No bethanechol-only control (healthy rats) was visible in the abstract, so an effect of bethanechol on mitochondria in uninjured tissue is untested in what was read. The pathway literature points the other way for M1 receptors: in SH-SY5Y cells and dorsal root ganglion neurons, M1 antagonists (pirenzepine, muscarinic toxin 7) raised mitochondrial membrane potential and OXPHOS protein expression via AMPK [7]. That paper did not test bethanechol and reported agonist data only for plasma membrane potential, so it is not used to grade this entry in either direction. Two further rat records from the same research group (Translational Research 2022; Life Sciences 2023) came up in a PubMed listing for bethanechol and mitochondria, but only their metadata were opened, so they are not counted [9][10].
• At-risk subgroups: None identified. The human oral dose (10 to 50 mg, three or four times daily) is not comparable with 12 mg/kg/day in rats.

Direction

Reverse (apparently protective in an injury model). Neither depletion nor excess of a nutrient.

Regulatory status

The bethanechol labels contain no mitochondrial or energy-metabolism statement [1][2][3].

Population evidence

Tier B, single study. Ongnok 2024, Molecular Neurobiology [6]: male Wistar rats given six doses of doxorubicin 3 mg/kg intraperitoneally; DOX-treated rats received PNU-282987 (a7 nicotinic agonist) 3 mg/kg/day, bethanechol (muscarinic agonist) 12 mg/kg/day, or both. The abstract reports that doxorubicin caused "defective mitochondrial ROS-detoxifying capacity, and dynamic imbalance" and that either agonist or the combination "potently attenuated neuroinflammation, mitochondrial dyshomeostasis, and Tau hyperphosphorylation." Sample sizes, bethanechol route and duration, the specific mitochondrial assays and effect sizes were not captured (abstract-level read through a summarizing fetch tool; full text not opened). Bethanechol was in the cohort, so the cohort test passes for this entry.

Mechanism

Not established. The abstract proposes acetylcholine receptor activation as protective against doxorubicin neuronal death. The labels state bethanechol does not cross the blood-brain barrier [1][2], so how oral or peripheral bethanechol would reach hippocampal mitochondria is unexplained in what was read.

Counter-evidence held on record

Framing caution for the consumer surface This is not a deficiency and not a reason to take any supplement. It is a single animal study in a chemotherapy-injury model and says nothing about the effect of bethanechol on mitochondria in people taking it for urinary retention. It must not be presented as a benefit.

Limits on what this shows

• Null and direction checks: A bladder organ-bath paper shows oxidative stress (cumene hydroperoxide) impairs muscarinic receptor function in pig detrusor, tested with carbachol, not bethanechol [8]. That is oxidative stress acting on the receptor, the opposite direction from the drug acting on redox state, so under the direction rule it is not evidence about bethanechol. A PubMed listing for bethanechol with oxidative stress, ROS, malondialdehyde and antioxidant terms returned 17 records, mostly salivary-gland, bladder and gut physiology titles, none of which was a human or animal study of bethanechol changing a redox marker by title [13] (titles only; most not opened).
• At-risk subgroups: None identified.

Direction

Reverse (apparently protective in an injury model); no evidence of increased oxidative stress from bethanechol.

Regulatory status

No antioxidant, oxidative-stress or redox statement in the labels [1][2][3].

Population evidence

Tier B, same single source as Mitochondrial burden [6]. The abstract names defective mitochondrial ROS-detoxifying capacity as part of the doxorubicin injury, but the part of the abstract read does not state which redox markers (for example MDA or antioxidant enzymes) were measured or whether bethanechol changed them specifically. This is the weakest yellow possible, held at yellow only because the redox defect is named in the abstract of a bethanechol-treated cohort.

Mechanism

Not established.

Counter-evidence held on record

Framing caution for the consumer surface Do not present as an antioxidant effect or as a reason to avoid or add antioxidants. The evidence is one animal abstract, and redox markers were not confirmed. Shares its source with the Mitochondrial burden entry (see Overlap map).

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or C source was found to support even a yellow grade, and no circulating claim about copper and bethanechol was found to rebut. This is a disclosed gap, not a finding of safety. Re-check PubMed, Europe PMC and Crossref for "bethanechol" with copper and ceruloplasmin when access is restored.

What was searched

Label text of three bethanechol DailyMed labels [1][2][3] (copper, iron, vitamin, mineral, electrolyte terms absent in the two labels searched for them [1][2]). Consumer depletion references [16][17]: bethanechol not listed. Direct drug-name searches on a depletion-retailer page returned 404. PubMed listing for bethanechol with copper, iron, ferritin, zinc, vitamin, magnesium and potassium terms: rate limited by the fetch proxy (429, request not to retry), twice in the original pass; a narrower copper/ferritin/iron-deficiency listing and a Crossref title query were also refused (429). Repair pass 2026-10-07, different phrasings: PubMed listing for bethanechol with copper, iron, ferritin and ceruloplasmin: 429 again; a web search for bethanechol with ferritin, iron deficiency, serum copper or hemoglobin in treated patients or case reports returned general copper-deficiency and nephrology case-report pages (three PMC pages hit bot verification or a redirect and could not be read; none was seen to name bethanechol by title); the web search budget was then exhausted.

Channel outcomes

Tooling-limited. No copper-specific bethanechol record was seen in any channel that could be read, but the decisive PubMed copper/ceruloplasmin listing was refused in both passes. A copper-specific bethanechol study cannot be ruled out from this review.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or C evidence and no circulating claim. A GI adverse-effect profile (cramps, diarrhea, nausea) does not itself imply iron loss, and that inference is not drawn here. Disclosed gap, not a finding of safety. Re-check when PubMed access is restored.

What was searched

Same channels as Copper, treated as an independent query set: labels [1][2][3] (no iron, anemia or hemoglobin term in the two labels searched), depletion references [16][17] (not listed), PubMed iron/ferritin/iron-deficiency listing (429, refused, in both the original and repair passes), Crossref title query (429), Semantic Scholar and Europe PMC (429 or blocked). The PubMed hemoglobin/anemia listing [14] did complete and its 18 titles contain no iron, ferritin or hemoglobin outcome in bethanechol users; one 1968 record on intrinsic factor secretion and pernicious anemia pathogenesis concerns the B12 axis and was seen by title only. Mechanism reasoning only: the label contraindicates peptic ulcer and the drug is a gastric motility stimulant; PubMed titles from the 1970s show bethanechol used as a gastric secretagogue in isolated canine stomach (titles only, not opened [14]). Increased acid secretion would not be expected to impair iron absorption, and no human iron measurement was found.

Channel outcomes

Tooling-limited. No iron-specific record was seen, but the decisive PubMed iron/ferritin listing was never completed. The completed hemoglobin/anemia listing is a partial null by title only.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or C source was retrieved in which bethanechol changed, or was tested for changing, the gut microbiome (the two bethanechol-containing records [21][22] measured motility and ion transport, not microbiome outcomes; the cholinesterase-inhibitor record is a different mechanism class and was not opened), and no circulating microbiome claim for bethanechol was found. Disclosed gap, not a finding of safety. Re-check when access is restored, including 16S studies in cholinergic or prokinetic treatment.

What was searched

Web search (3 phrasings in the original pass, 1 more in the repair pass): "bethanechol gut microbiome OR microbiota OR dysbiosis cholinergic agonist intestinal bacteria"; "bethanechol treatment mice fecal microbiota 16S composition changed cholinergic"; "bethanechol small intestinal bacterial overgrowth OR Clostridioides difficile OR dysbiosis motility prokinetic"; and in the repair pass "bethanechol treatment effect on gut microbiota composition fecal 16S sequencing" (extended mode), which returned antibiotic, IBD, choline and beta-blocker microbiome papers and no bethanechol record. Earlier results were patents on SIBO, a pyridostigmine (a cholinesterase inhibitor, not a muscarinic agonist) gut-microbiome record seen by title only, and a 2026 Nature Microbiology paper on microbial ammonia and colonic acetylcholine that was opened and does not mention bethanechol [15]. One PMC record (PMC6206996) returned a bot-verification page and was not read. In the repair pass a PubMed listing for bethanechol with microbiota, microbiome or dysbiosis completed and returned two records [23]. Both were opened. Moyat 2022, Mucosal Immunology [21]: in germ-free and antibiotic-treated mice, microbiota depletion lowered intestinal acetylcholine and altered motility, and bethanechol (20 mg by oral gavage) restored motility and larval distribution; microbiota composition was not measured after bethanechol. Lomasney 2014, Neurogastroenterology and Motility [22]: in Ussing chamber colon preparations, absence of the microbiota did not change the tissue response to bethanechol. In both papers the direction is the microbiota acting on host motility or on the response to bethanechol, not bethanechol acting on the microbiome. Other repair-pass channels: OpenAlex, Crossref and Europe PMC searches remained blocked (429).

Channel outcomes

Open web search and the completed PubMed microbiota listing show no study in which bethanechol was given and microbiome composition, diversity or function was measured. Two bethanechol-containing records were found and read, and both are direction-reversed or null for this question. The listing returned only two records and the summarizing tool may have truncated it, so a thin literature is likely but not proven. Bethanechol increases gut motility and causes diarrhea (label [2]), a plausible route to microbiome change, but plausibility without any study is not graded here.

Limits on what this shows

• Null and contrary findings: No human data. A PubMed listing for bethanechol with hemoglobin, anemia, methemoglobin, hemolysis and oxygen consumption (18 records [14]) contained no hematologic outcome in bethanechol users by title or abstract where shown. One 1968 record on intrinsic factor secretion and pernicious anemia pathogenesis was seen by title only, concerns the B12 axis and not oxygen delivery, and was not opened. A web search for bethanechol with methemoglobinemia, hemolysis or anemia returned general methemoglobinemia pages and a drug side-effect page; none was opened and none was seen to name bethanechol by title. Concentrations used ex vivo are not comparable with human oral dosing (10 to 50 mg three or four times daily).
• At-risk subgroups: The label contraindications (coronary artery disease, bradycardia, hypotension, asthma) mark the human subgroups in which this pharmacology matters [1][2]. This is a drug-safety matter, not a nutrient matter.

Direction

Neither depletion nor excess of a nutrient. Reduced coronary flow with reduced oxygen consumption (lower demand) in an ex vivo organ. Filed as a mechanism clarification under Hard Rule 2, not as an oxygen-delivery deficiency.

Regulatory status

The bethanechol labels contain no hemoglobin, anemia or blood dyscrasia statement [1][2][3]. They do list bradycardia, hypotension and coronary artery disease among the contraindications [1][2], which is the human-facing counterpart of this cardiovascular pharmacology.

Population evidence

Tier B, three ex vivo rat heart studies with bethanechol in the cohort. Nuutinen, Wilson and Erecinska 1985, J Mol Cell Cardiol [18]: acetylcholine and three analogues (bethanechol, carbachol, methacholine) gave "vasoconstriction in both types of preparations and this vasoconstriction was accompanied by a decrease in oxygen consumption" (abstract text as returned by a summarizing fetch tool from a PubMed listing page; full text not opened). Sakai 1980, Br J Pharmacol [19]: in donor blood-perfused rat hearts, small bethanechol doses lowered perfusion pressure with little change in left ventricular pressure or heart rate, larger doses raised perfusion pressure (vasoconstriction) and lowered left ventricular pressure and heart rate, and responses were antagonized by small doses of atropine. Zhang and Hoover 2000, J Pharmacol Exp Ther [20]: bethanechol was the principal agonist for coronary vasoconstriction, with perfusion pressure as the readout. Sample sizes, bethanechol concentrations and per-agonist oxygen consumption values were not captured. None of the three measured hemoglobin, hematocrit, red-cell mass or arterial oxygenation.

Mechanism

Named: muscarinic receptor mediated coronary smooth muscle contraction through voltage-independent receptor-operated Ca2+ channels, voltage-operated Ca2+ channels and protein kinase C [20], atropine-sensitive [19]; reduced cardiac work lowers oxygen demand [18].

Counter-evidence held on record

Framing caution for the consumer surface Do not present as anemia, low hemoglobin or poor oxygen carrying capacity, and not as a reason to take iron or any supplement. It is the drug's intended muscarinic pharmacology seen in rat hearts. Shares its source with the ATP production entry (see Overlap map).

Limits on what this shows

• Null and contrary findings: The one bethanechol mitochondrial record [6] reports mitochondrial dyshomeostasis, not ATP, respiration or membrane potential. An M1 antagonist paper [7] raised mitochondrial membrane potential and OXPHOS proteins in neuronal cell models, but bethanechol was not tested and the paper is context only. A JoVE protocol titled for cholinergic ligand-dependent modulation of oxidative phosphorylation was opened in the repair pass and returned no readable content, so it was not read. The mitochondria PubMed listing [12] was reviewed by title only and showed ATP as a purinergic transmitter, not as energy output.
• At-risk subgroups: None identified.

Direction

Reverse or neutral (energy state rose as work fell). No evidence that bethanechol impairs ATP production.

Regulatory status

No energy-metabolism or ATP statement in the labels [1][2][3].

Population evidence

Tier B, single source [18], held at yellow as the weakest case. The abstract text returned by a summarizing fetch tool states that the agonists, which included bethanechol, decreased cardiac work and increased the myocardial energy ratio. Which energy ratio was measured (for example a phosphorylation potential), whether ATP itself was directly quantified, and whether the energy-ratio result was reported for bethanechol specifically rather than for the agonist group were not confirmed. Full text not opened.

Mechanism

Not established by the abstract. The plausible reading is that lower contractile work reduces ATP turnover and raises the energy ratio; this is not a mitochondrial effect of the drug.

Counter-evidence held on record

Framing caution for the consumer surface Do not present as an energy or ATP effect of bethanechol in people, as a benefit, or as a reason to take any supplement. It is one abstract from an ex vivo rat heart study. Shares its source with the Oxygen delivery/utilization entry (see Overlap map).